Acknowledging the kind of traction gained by this market, recently published a study report asserts the Lab Furniture market is expected to reach USD 2247.5 million by 2027, registering a phenomenal CAGR of 6.32% during the review period (2022 to 2027).
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
Chronic inflammatory demyelinating polyneuropathy is defined as a nervous disorder in which the body immune system attacks myelin which is an important part of the nervous system. It happens when the body resilient system cannot distinguish between the body’s own cell and foreign cell and instead start destroying the healthy cells of the body. This can cause pain, impaired ability, loss of sensation, chronic fatigue and other problems, Different actions can be used to treat this illness such as intravenous immunoglobulin, plasmapheresis, physiotherapy and others.Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder important to faintness and loss of feeling in legs and arms. It occurs due to the indecorous reaction of the body’s immune system and destructive myelin sheath. Myeline sheath environs the outlying nerves system and acts as an insulator for the nerves to conduct desires properly. Indications of ongoing inflammatory demyelinating polyneuropathy (CIDP) includes tingling, numbness or altered feeling, which often begins in hand and feet, weakness in arms and legs, fatigue, muscle pain, and others.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is more prominently observed in men than in women. The active government support through consciousness agendas and drug supports is expected to positively impact the global chronic inflammatory demyelinating polyneuropathy therapeutics market. Furthermore, the FDA approval for Hizentra, a subcutaneous immunoglobulin manufactured by CSL Behring in March 2018, is projected to hurry the request for chronic inflammatory demyelinating polyneuropathy drugs.
Who are the Major Players in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The global chronic inflammatory demyelinating polyneuropathy includes identification and analysis of the various market participants competing in the global market. Prominent competitors include Kedrion S.p.A, Octapharma, CSL Behring, Pfizer Inc, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Baxter, Bio Products Laboratory Ltd., Grifols, and Teijin Pharma Limited.
Industry News -
Apr 12, 2022: Kedrion Announces Exercise Of Early Redemption Of Notes Maturing In July 2022
Kedrion S.p.A. announces the exercise of the residual maturity call option embedded in its €350,000,000 bond maturing on 12 July 2022 (the “Notes”) and bearing a 3.000 per cent. coupon (ISIN code: XS1645687416), of which €200,009,000 remain outstanding as of the date hereof. Pursuant to the terms and conditions of the Notes, this option allows the Company to redeem at par, all the outstanding Notes starting from 90 days prior to their maturity date
2022-04-05: Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ST Set used in continuous renal replacement therapy (CRRT).
What are the major Applications, Types and Regions for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
By Types,
- Corticosteroids
- Immunoglobulin
- Others
The Application is segmented into spinal fluid analysis, electrodiagnostic testing, electromyography, nerve conduction testing, and others.
By Application ,
- Hospitals
- Specialty Neurological Clinics
- Research & Academic Laboratories
- Others
The market is segmented into hospitals, specialist neurology clinics and research & academic labs, amongst others.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional Analysis
The Americas, Europe, Asia Pacific, and the Middle East & Africa. The global chronic inflammatory demyelinating polyneuropathy market has witnessed the highest presence in the Americas market. Possessing a share of 52% of the global market, the Americas have a leadership position in the market due to the presence of a significant pool of patients suffering from CIDP. Moreover, the strong presence of several leading players in the market is expected to reveal opportunities for growth. The America’s developed countries have a highly advanced healthcare system which makes the diagnosis of chronic inflammatory demyelinating polyneuropathy easier, thus supporting the regions market position.
Meanwhile, the Asia Pacific is being projected as the fastest growing regional chronic inflammatory demyelinating polyneuropathy market at a CAGR of 7.03% during the review period. The region has an increased availability of funds for research and development activities due to a growing focus on healthcare and healthcare reform. Moreover, the presence of significant expertise in the region is likely to encourage market growth in the coming years.
Notably, the Middle East and Africa market is also expected to grow at a significant pace due to the presence of emerging economies where the healthcare sector is developing swiftly. Middle Eastern countries, in particular, are anticipated to drive market growth.
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East & Africa
- Latin America
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
What is our Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market report scope?
Report Attributes
|
Report Details
|
Forecast Period 2022 to 2028 CAGR
|
CAGR of 6.32% during the review period (2022 to 2027).
|
By Type
|
- Corticosteroids
- Immunoglobulin
- Others
|
By Application
|
- Hospitals
- Specialty Neurological Clinics
- Research & Academic Laboratories
- Others
|
By Companies
|
Kedrion S.p.A, Octapharma, CSL Behring, Pfizer Inc, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Baxter,
|
Regions Covered
|
- North America
- Europe
- Asia-Pacific
- Rest of the World
|
Countries Covered
|
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
|
Base Year
|
2022
|
Historical Year
|
2017 to 2021
|
Forecast Year
|
2022 to 2027
|
Number of Pages
|
150
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Key Takeaways from this Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Report
- Evaluate Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.
- Understand the different dynamics influencing the market - growth driving factors, specific challenges and hidden opportunities.
- Get in-depth insights on your competitor performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis and more.
- Analyze the sales and distribution channels across geographies to enhance top-line revenues.
- Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies in your processes.
- Get a quick outlook on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market entropy - M&A's, deals, partnerships, product launches of all key players for the past 5 years.
- Evaluate the import-export statistics, supply-demand and competitive landscape for more than top 20 countries globally for the market.
All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.
Frequently Asked Question -
What is the study period of this market?
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market is studied from 2022-2027.
Who are the prime players in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Kedrion S.p.A, Octapharma, CSL Behring, Pfizer Inc, Shire, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Baxter
Which region held the largest share in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
United States, Europe, China, Japan, Southeast Asia, India and Rest of World
What are the significant types of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Corticosteroids, Immunoglobulin, Others
What are the major end-use applications of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
